Top News from Cardiology Conferences in 2022

Published on: 

Our editorial team is celebrating the final week of the year by recapping some of our most popular stories and content from the past year. Here, we are highlighting our most popular content from the American College of Cardiology, European Society of Cardiology, and the American Heart Association annual meetings.

Top News from ACC.22

ACC, AHA, and HFSA Partner to Release 2022 Heart Failure Guidelines

Released on the eve of ACC.22, the 2022 heart failure guidelines represent a collaborative effort by the ACC/AHA/HFSA and include major additions, including a new focus on the use of SGLT2 inhibitors and revisions to the ACC/AHA stages of heart failure.

SODIUM-HF: Reduced Sodium Intake Fails to Reduce Heart Failure Events

Data from SODIUM-HF indicates reduction of dietary sodium intake was not associated with a statistically significant reduction of a composite of all-cause death, cardiovascular-related hospitalizations, and cardiovascular-related emergency department visits.

Mavacamten Can Reduce Need for Surgery in Hypertrophic Cardiomyopathy

Results of the VALOR-HCM trial indicate patients with hypertrophic cardiomyopathy could reduce their need for septal reduction therapy and improve quality of life with use of mavacamten, a selective cardiac myosin inhibitor from Bristol Myers Squibb.

Top News from ESC Congress 22

Dapagliflozin Proves HFpEF Benefit in DELIVER Trial

Presented at ESC Congress 22, results of the DELIVER trial indicate use of dapagliflozin (Farxiga) was associated with an 18% reduction in the primary outcome, with a 21% reduction in risk observed for worsening heart failure and a 12% reduction in risk observed for cardiovascular death compared with placebo therapy.

DANCAVAS: Universal CVD Screenings Do Not Reduce Risk of Death in Men

Results of a trial assessing the impact of universal subclinical CVD screenings found increased screenings did not significantly reduce the risk of all-cause mortality in men aged 65-74 years over the next 5 years.

TIME Study: No Added Benefit from Nighttime Dosing of Blood Pressure Medications

Although the Hygia study suggested nighttime dosing could increase the benefit of risk reduction obtained from antihypertensive medications, the TIME study found no significant improvement in risk reduction afforded by nighttime dosing as compared to morning dosing of medication.

Top News from AHA 22

STRONG-HF: In-Hospital Initiation of GDMT Reduces Rehospitalization, Mortality Risk in Heart Failure Patients

Results of the STRONG-HF trial provide the first evidence from a randomized clinical trial that rapid, in-hospital initiation of guideline-directed medical therapy in heart failure can improve patient outcomes.

SPORT: Supplements Fail to Lower LDL-C in Primary Prevention Population

Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.

Ocean(a)-DOSE: Olpasiran Shows Promise for Lowering Lipoprotein(a)

Results of the Ocean(a)-DOSE trial, a phase 2 dose-finding study presented at AHA 22, suggests use of olpasiran dosed at 75 mg or higher every 12 weeks was associated with a reduction of Lp(a) among 95% of patients.